ENDRA Life Sciences Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.6M
- Price
- $4.49
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.07%
- Volume
- 27.4K
About
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Quick stats
Shares outstanding1.3M
Computed float1.2M
Float / shares92.1%
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001681682
Websitehttps://www.endrainc.com
AI Summary
AI-generated1/19
criticalbullishm and a
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
ENDRA signed a definitive merger agreement with Noble Africa and ASP Isotopes, planning to pivot into the helium market via the Renergen Virginia Gas Project and rename itself Noble Africa Inc.
The transaction is backed by a $50 million private placement to Noble Africa, with closing anticipated in Q4 2026 subject to stockholder and regulatory approvals.
Q2 results showed net income of approximately $160,000, aided by digital asset gains, while operating expenses were cut by 39% in R&D and 92% in sales and marketing to preserve cash.
Red flags
- Low cash runway ($1.7M unrestricted) relative to quarterly burn ($0.9M), making merger completion critical for ongoing operations